Lisata 治疗学合作伙伴与加泰隆尼亚公司合作,推进Certepetide,这是针对多种固态肿瘤的一个很有希望的抗体药物共产体。 Lisata Therapeutics partners with Catalent to advance certepetide, a promising antibody-drug conjugate for multiple solid tumors.

Lisata治疗学与Catalent公司合作,推进了Certepetide,这是一个铅分子,在多种固态肿瘤中具有潜力,特别是在抗体-药物共生(ADC)类癌症治疗中。 Lisata Therapeutics has partnered with Catalent to advance certepetide, a lead molecule with potential across multiple solid tumors, particularly in the antibody-drug conjugate (ADC) class of cancer treatments. 随着ADCs获得主要制药公司之间的牵引力,合作凸显了分子的广泛适用性和巨大的商业潜力。 The collaboration highlights the molecule’s broad applicability and significant commercial potential as ADCs gain traction among major pharmaceutical firms. 这项交易反映了Lisata通过战略工业联盟扩大其肿瘤管道的战略。 The deal reflects Lisata’s strategy to expand its oncology pipeline through strategic industry alliances.